We blend human insight with safe and fast data access to train high performance models.

Collaborate

Accessing data at scale requires new ways of collaborating.

We combine cutting-edge technologies, like federated learning, with critical clinical expertise and a network of academic researchers. This allows research to be accelerated in a safe and privacy-preserving way.

Tip arrowTip arrowTip arrow

Challenges

What if we could share global data insights seamlessly?

Strict regulation to protect patient data

Regulatory requirements such as GDPR and HIPAA and a fear of compromising competitive assets or patient privacy makes data sharing complex.

Disjointed data

Complementary datasets cannot be easily accessed and combined for model training.

Data harmonization

Differing standards of data structure, digitization, storage, privacy compliance, and geographical distribution stack up and compound each other.

Strict regulation to protect patient data

Regulatory requirements such as GDPR and HIPAA and a fear of compromising competitive assets or patient privacy makes data sharing complex.

Disjointed data

Complementary datasets cannot be easily accessed and combined for model training.

Data harmonization

Differing standards of data structure, digitization, storage, privacy compliance, and geographical distribution stack up and compound each other.

Owkin’s solution

We unite Clinical, IT and Data specialists and groundbreaking technologies within an integrated network to overcome these challenges for faster and more effective research.

Federated Learning

arrow-desktop
arrow-mobile

Federated Learning

Connect disjointed data to build accurate models without sharing or pooling data with Federated Learning

Read more

Unlocking access

Federated learning powers precision medicine by unlocking access to the right quality and quantity of data to train high-performance models.

Data stays local

With Federated Learning the data stays local - only models and insights travel between the servers, protecting privacy and ensuring compliance.

More accurate models

This technology allows research communities to benefit from access to more datasets, capturing the full heterogenous picture, resulting in more robust and accurate models.

group-working

Testimonial

01/01

background-shapes

“In terms of security, Owkin provided the methodology, as well as the external audits which, for us, are a guarantee of security. Owkin’s philosophy of excellence and speed is closely aligned to that of cancer centers – there’s a great cultural fit. Today, if we wanted to apply AI to our data, I wouldn’t think twice – I’d call Owkin.”

Thierry Durand

Head of IT Systems at Centre Léon Bérard

Thierry Durand

Owkin Connect

arrow-desktop

Owkin Connect

arrow-mobile

Expand access to health data while protecting privacy with our Federated Learning software, Owkin Connect.

Read more

Owkin Connect technology powers collaboration in healthcare by ensuring data confidentiality and compliance.

Owkin Connect for clinical research

The HealthChain project unites AI experts and medical researchers to foster medical innovation in anatomo-pathology, dermato-oncology and fertility while preserving patients' privacy. Requirements such as GDPR and HIPAA and a fear of compromising competitive assets or patient privacy makes data sharing complex.

BioPharma companies and healthcare institutions deploy Owkin Connect in various settings for clinical research and drug discovery.

Owkin Connect for drug discovery

Owkin Website

The MELLODDY Consortium tackles the $1.3Bn challenge of bringing a new drug to market. This project enhances predictive machine learning models on the decentralized data of 10 pharmaceutical companies, without exposing proprietary information.

Consortia

arrow-desktop

Consortia

arrow-mobile

Accelerate your breakthrough research by building collaborative projects in a privacy-preserving way with Federated Learning.

Free up resources from data pooling and management work packages to focus on what really matters: your scientific question. Our decentralized-AI technology lets you set up secure and efficient consortia: data is never shared between partners; only the encrypted models travel between the data centers.

Data & KOL network

arrow-desktop

Data & KOL network

arrow-mobile

Solve the biggest questions in cancer by combining the very best biomedical expertise with artificial intelligence. Owkin has built a world-class research network of leading academic centers, KOLs and expertly-curated, high-quality patient data.

Owkin’s data network contains cohorts of rich longitudinal datasets that medical experts have curated for fit-for-purpose standard and AI analysis. They span many modalities; omics, imaging, histology, and clinical data, comprehensively capturing oncology’s heterogeneous nature.

Collaboration in healthcare

Owkin is proof that collaboration in healthcare could make precision medicine a reality.

Through data access and KOL insight, we’ve created breakthrough models

Professor Fabrice André, MD, PhD

Professor Fabrice André, MD, PhD

Director of Research Gustave Roussy

"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."

Professor Julien Calderaro, MD, PhD

Professor Julien Calderaro, MD, PhD

Professor of Pathology at Henri Mondor University Hospital

“Artificial intelligence will allow the extraction of a massive amount of clinically useful data from histological slides. We have shown that AI can outperform every classical prognostic factor in liver cancer.”

Professor Francoise Galateau Salle, MD, PhD

Professor Francoise Galateau Salle, MD, PhD

Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard

“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”

Professor William R. Jarnigan , MD

Professor William R. Jarnigan , MD

Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center

“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”

Professor Fabrice André, MD, PhD

Professor Fabrice André, MD, PhD

Director of Research Gustave Roussy

"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."

Professor Julien Calderaro, MD, PhD

Professor Julien Calderaro, MD, PhD

Professor of Pathology at Henri Mondor University Hospital

“Artificial intelligence will allow the extraction of a massive amount of clinically useful data from histological slides. We have shown that AI can outperform every classical prognostic factor in liver cancer.”

Professor Francoise Galateau Salle, MD, PhD

Professor Francoise Galateau Salle, MD, PhD

Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard

“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”

Professor William R. Jarnigan , MD

Professor William R. Jarnigan , MD

Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center

“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”

Some of our partners

Latest Publications

Metrics

168 & 40

168 KOLs; 40 have a H-index above 44

14

14 leading academic research centres equipped with federated technology

8

8 consortia of leading biopharma and research partners (4 IMI projects and 2 H2020 grants)

45

Access to 45 live datasets & continuously expanding

168 & 40

168 KOLs; 40 have a H-index above 44

14

14 leading academic research centres equipped with federated technology

8

8 consortia of leading biopharma and research partners (4 IMI projects and 2 H2020 grants)

45

Access to 45 live datasets & continuously expanding

arrow

Our data network

Owkin-Map-Rebrand-1Owkin-Map-Rebrand-1